GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sanara MedTech Inc (NAS:SMTI) » Definitions » EBIT
中文

Sanara MedTech (Sanara MedTech) EBIT : $-3.96 Mil (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Sanara MedTech EBIT?

Sanara MedTech's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $0.03 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.96 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sanara MedTech's annualized ROC % for the quarter that ended in Dec. 2023 was -15.22%. Sanara MedTech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 2.48%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sanara MedTech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -1.38%.


Sanara MedTech EBIT Historical Data

The historical data trend for Sanara MedTech's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanara MedTech EBIT Chart

Sanara MedTech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.73 -4.43 -7.99 -13.94 -3.96

Sanara MedTech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.16 -1.22 -1.87 -0.91 0.03

Competitive Comparison of Sanara MedTech's EBIT

For the Medical Instruments & Supplies subindustry, Sanara MedTech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sanara MedTech's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sanara MedTech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sanara MedTech's EV-to-EBIT falls into.



Sanara MedTech EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sanara MedTech  (NAS:SMTI) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sanara MedTech's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-8.724 * ( 1 - 0% )/( (57.653 + 56.998)/ 2 )
=-8.724/57.3255
=-15.22 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Sanara MedTech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0.1/( ( (3.421 + max(0.405, 0)) + (3.253 + max(0.975, 0)) )/ 2 )
=0.1/( ( 3.826 + 4.228 )/ 2 )
=0.1/4.027
=2.48 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(7.436 + 5.021 + 0.621) - (11.673 + 0 + 1)
=0.405

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(8.475 + 4.718 + 0.608) - (11.726 + 0 + 1.1)
=0.975

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sanara MedTech's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=-3.964/286.886
=-1.38 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sanara MedTech EBIT Related Terms

Thank you for viewing the detailed overview of Sanara MedTech's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Sanara MedTech (Sanara MedTech) Business Description

Traded in Other Exchanges
N/A
Address
1200 Summit Avenue, Suite 414, Fort Worth, TX, USA, 76102
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are HYCOL Hydrolyzed Collagen, BIAKOS Skin and Wound Cleanser and BIAKOS Skin and Wound Gel.
Executives
Eric D Major director 751 MILLER DRIVE SE, LEESBURG VA 20175
Zachary B. Fleming officer: President - Surgical Div. 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Shawn M. Bowman officer: President - Wound Care Div. 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Rebecca E Mcmahon officer: President - R&D 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Sara N Ortwein director 5959 LAS COLINAS BOULEVARD, IRVING TX 75039-2298
Robert Andrew Desutter director 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Eric D Tanzberger director 1929 ALLEN PARKWAY, HOUSTON TX 77219
Christopher A. Morrison officer: President - Telehealth Svcs. 1200 SUMMIT AVENUE, SUITE 414, FORT WORTH TX 76102
Roszell Iii Mack director 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Cgi Cellerate Rx, Llc 10 percent owner C/O THE CATALYST GROUP, INC., 7500 RIALTO BLVD., BLDG. II, SUITE 220, AUSTIN TX 78735
Catalyst Rochal, Llc 10 percent owner C/O THE CATALYST GROUP, INC., 7500 RIALTO BLVD., BLDG. II, SUITE 220, AUSTIN TX 78735
Bradley J. Gurasich 10 percent owner C/O THE CATALYST GROUP, INC., 7500 RIALTO BLVD., BLDG. II, SUITE 220, AUSTIN TX 78735
J Michael Carmena director, officer: Principal Executive Officer 1200 SUMMIT AVE STE 414, FORT WORTH TX 76102
Michael D. Mcneil officer: Chief Financial Officer 1200 SUMMIT AVE, STE 414, FORT WORTH TX 76102
Catalyst Group, Inc. 10 percent owner 1375 ENCLAVE PARKWAY, HOUSTON TX 77077

Sanara MedTech (Sanara MedTech) Headlines